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Abstract 
 
Despite the inclusion of equity ideals in the design of many health care systems, pragmatic tools for 
integrating them into the efficiency categories of cost-effectiveness in HTA remain under-developed.  
This paper reviews approaches used to incorporate equity in HTA methods and develops a 
framework to help decision makers supplement the standard efficiency criteria of HTA and avoid 
building inequities, explicit or implicit, into their methodology.  $µFKHFNOLVW¶LVSURYLGHGWRDOHUWGHFLVLRQ
makers to a wide range of equity considerations for HTA.  This checklist is intended to be used as 
part of the process through which advisory bodies receive their terms of reference; the scoping of the 
agenda prior to the selection of a candidate intervention and its comparators for HTA; the 
accompanying background briefing for decision makers; and as a tool to help to structure the 
GLVFXVVLRQDQGFRPSRVLWLRQRISURIHVVLRQDODQGµOD\¶DGYLVRU\JURXSVGXULQJWKHDVVHVVPHQWSURFHVV  
The checklist is offered as only a beginning of an on-going process of deliberation and consultation, 
through which the matters covered can be expected to become more comprehensive and the record 
of past decisions and their contexts in any jurisdiction adopting the tool can serve to guide 
subsequent evidence gathering and decisions.  In these ways, it may be hoped that equity will be 
more systematically and fully considered and implemented in both the procedures and decisions of 
HTA.  
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Introduction 
 
A challenge was recently presented to Health Technology Assessment (HTA) practitioners to address 
equity better in their analyses [1].  In this paper we attempt to meet that challenge, at least in part.  
HTA is the systematic evaluation of the consequences of the use of a health care intervention 
KHQFHIRUWK µWHFKQRORJ\¶  Its principal purpose is to inform decision-making.  Ethical considerations 
and non-economic social consequences were included in early general formulations of HTA [2].  
However, it is only recently that attempts have been made to develop frameworks for considering 
methods of integrating ethics and a wider set of social consequences into HTA [3-7].  A 
comprehensive attempt to give practical guidance is that of the National Institute for Health and 
Clinical Excellence (NICE) in England and Wales [6].  One important ethical consideration is equity.  
Despite the significance of equity ideas in the design of many health care systems, pragmatic tools for 
integrating them into the efficiency categories of cost-effectiveness in HTA remain under-developed 
[8].  We attempt here a first step towards a pragmatic solution by providing a framework of equitable 
considerations of potential relevance in HTA decision making, giving examples of the ways in which 
such considerations might arise, and providing a summarized checklist which may itself be used as a 
decision tool by HTA decision makers or which could be further abbreviated as a desk-top aide-
memoire.  The framework is primarily intended for high-level decision makers who specify the criteria 
to be used by HTA advisory committees.  The checklist if offered as a first approximation to a practical 
tool for use by such advisory committees. 
 
Equity has many meanings in both academic and lay contexts [9-12].  The absence of an agreed 
theory of equity arises out of the absence of a general or monist theory of morality.  There are moral 
theories that claim to be general, such as utilitarianism, though utilitarianism in its classical form is not 
directly concerned with equity.  Non-utilitarian theories hold, variously, that the equitable distribution of 
health care resources is that which is to the advantage of the least advantaged person - so-called 
maximin theory.  Deontological theory posits that an equitable distribution arises out of the duty each 
has to provide for others.  Entitlement theory holds that an equitable distribution is the outcome of an 
equitable economic and social system (for a review of rival approaches see Veatch [13]).  We do not 
attempt the Sisyphean tasks of selecting from or reconciling rival philosophies but suggest instead 
that equity issues concerning the use of health care resources in a decision-making context are best 
considered explicitly as pluralist.  Rather than defining a priori ZKDW µHTXLW\¶ LV ZH GUDZ RQ D
multidisciplinary literature and our own practical experience, to create an eclectic list of equity issues, 
which, if left unaddressed by decision makers, could be deemed by a reasonable person to be unfair 
or to lead to unfairness in the adoption, diffusion or consequences of a health technology.  
 
Two domains of equity are especially relevant in HTA.  One is fairness of the procedures used in the 
conduct of HTAs.  The other is equity as a decision criterion, like efficiency, for ranking health care 
interventions.  Equity in the first sense has, at least in part, been conceptuaOL]HGDVµDFFRXQWDELOLW\IRU
UHDVRQDEOHQHVV¶[10, 14-16] and has been adopted by some agencies (e.g. NICE 2008).  Equity in the 
second sense is a statutory requirement in several jurisdictions and is likely to be increasingly 
required: illegal discrimination will need to be addressed in all jurisdictions, such as the UK, where 
such legislation exists.  However, such imperatives typically address only a subset of the concerns for 
equity that can arise in HTA.  Unfortunately, there exists no substantive body of principled thinking 
that can serve as a sure, or even moderately agreed, foundation for a more comprehensive treatment 
of equity in HTA [11]. 
 
Equity in the sense of fairness in the way health care is financed, produced and distributed has been 
a founding principle of many health care systems throughout the world, and has resulted in systems 
that broadly fund activity according to ability to pay and distribute it according to need (especially in 
middle and high income countries).  It would therefore seem appropriate for HTA equity criteria in 
such jurisdictions to be at least consistent with these broader ideals of health care.  Unfortunately 
there are major differences betwHHQGHILQLWLRQVRI µQHHG¶PHDVXUHVRI LW DQG LWVDSSOLFDWLRQ LQ+7$
decisions [12] and it is far from clear what a criterion of need would require over and above the criteria 
of effectiveness and cost-effectiveness. 
 
The standard approach to equity within HTA seems to operate at two distinct levels.  The first is 
general, such as being aware of the difference between horizontal and vertical equity (noting that only 
the former involves attempting to achieve equity through the equality of something [9, 17]) or having 
an equal respect for everyone.  Since not all inequalities are inequitable, nor all equalities equitable, 
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we agree with Whitehead (1991) in making equity and inequity the focus of our attention rather than 
equality or inequality [18].  The second is specific, such as the application of differential weights to 
costs and benefits according to particular equity-related characteristics of those likely to be affected 
by the decision [19-27]).  While there is merit in this outcome-based approach, in practice decision 
makers have difficulty in identifying circumstances in which departures from strict equality in the value 
of units of outcome could be justified, with the possible exception of end-of-life benefits which NICE, 
for example, explicitly treats as warranting special weights, but without specifying them in quantitative 
WHUPVDQGZKLFKRWKHUVVXFKDV2QWDULR¶V&RPPittee to Evaluate Drugs (CED), favour - though only 
implicitly1.  Equity-IRFXVHG µLPSDFW DVVHVVPHQWV¶ DUH H[DPSOHV RI SURFHGXUHV WKDW KDYH D IRFXV
specifically on the distribution of outcomes (e.g. Kemm et al 2006 [29]). 
 
There is little guidance concerning what, justly, ought to constitute either the characteristics in 
question or the size of the weights.  6RPH JDWKHU HYLGHQFH UHJDUGLQJ WKH SXEOLF¶V SUHIHUHQFHV, 
VWDNHKROGHUV¶ SHUVSHFWLYHV RU H[SHUWV¶ DGYLFH RQ either of these matters [26, 27, 30-36].  Empirical 
HIIRUWVWRGLVFRYHUZKDWµWKHSXEOLF¶WKLQNVDERXWDSSURSULDWHZD\VRIWUDGLQJ-off benefit with cost also 
raise the fundamental ethical question of the extent to which HTA ought to embody such values, even 
when participants are well-informed.  It is possible that preferences may be unstable or that the values 
elicited change according to the amount of information that is given, the technology considered, 
whether the health state in question is merely anticipated or actually experienced.  Even when all 
such confounders have been taken into account it is possible for there to be considerable variance 
around population means and the distribution of ethical values need not have a single mode.  
Ethicists might raise the objection that what is just or fair is not to be determined by populist vote, 
while others might contend that the preferences of elected representatives of the community in 
question should count rather than the preferences of those who elected them.  Other methods have 
sought generalizable trade-offs between equity and efficiency [37, 38].  However, not all equity issues 
involve trade-offs with efficiency2 [40] and none of these approaches addresses what ought to be 
done nor attempts to address the many other dimensions of equity that ought to be taken into 
account.  The dimensions of equity typically considered (at least by health economists) are quite 
restrictive, being mostly concerned with distributive fairness and focused on health, the geography of 
health care, and income.  Further, irreconcilable differences in values are glossed over, hidden 
stereotyping happens and reliance, save in the case of legislated requirements, is almost entirely 
upon intuition. 
 
We propose the creation of a pluralist [41] µFKHFNOLVW¶ WKDWPLJKWEHH[SDQGHGDQGGHYHORSHG LQWKH
light of experience, consultation, deliberation and the transparency that ought to accompany it.  In any 
specific decision context, not all the items in the checklist will be relevant ± and perhaps none will be 
± but the intent is to minimize the risk of overlooking considerations of equity that might be relevant by 
ensuring that minds are open to matters that can easily be overlooked or, if not overlooked, that may 
be difficult to articulate, appraise or measure.  
 
                                                 
1
 ,QWKH8.WKH'HSDUWPHQWRI+HDOWK¶VUHFHQWFDOOIRUSURSRVDOVUHJDUGLQJYDOXH-based pricing for pharmaceuticals explicitly 
invites proposals regarding weights (see [28]). 
2
 Equity is commonly perceived as in conflict with efficiency. The existence of any trade-off hinges, however, on the concept of 
µHIILFLHQF\¶HPSOR\HG,IEHLQJHIILFLHQWLVWRPD[LPLVHDJJUHJDWHSRSXODWLRQKHDOWKZLWKfixed weights for LWVPHPEHUV¶KHDOWK
states (say, equal weights), then any such weights are potentially inequitable, and could generate a clash (say, on grounds of 
neglecting previous histories of ill-health, or of treating a given health gain as of equal social value regardless of the starting 
health state of individual members). But this clash is between different approaches to weighting health states, and less to do 
with efficiency. If, on the other hand, efficiency is of the conventional kind in economics (e.g. Barr 2004 [39]) ± a state of affairs 
LQZKLFKQRRQH¶VKHDOWKFDQEHLQFUHDVHGZLWKRXWWKHQHFHVVLW\RIUHGXFLQJVRPHRQHHOVH¶VWKHQWKHUHLVDYLUWXDOO\XQOLPLWHG
VHWRIGLIIHUHQWO\ZHLJKWHGFRPELQDWLRQVRIPHPEHUV¶KHDOWKVWDWHVDQ\RQHRIZKLFKLVHIILFLHQWEXWRQO\DIHZHTXLWDEOH7he 
real trade-off is again between rival conceptions of what it means to be equitable. 
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A proposed initial checklist 
 
We propose a practical and adaptable iQLWLDO IUDPHZRUN WKH µHTXLW\ FKHFNOLVW¶ DV WKHEDVLV IRU WKH
development of a more comprehensive typology3.  It is practical because it is intended as a sequence 
RIµUHGIODJV¶WRDOHUWGHFLVLRQPDNHUV± and the designers of the systems within which they work ± to 
matters of equity that might warrant integration into the usual efficiency analysis of HTAs.  It is 
adaptable because the checklist as it currently stands is intended only as an initial step and what may 
be added is currently unknowable (at least, by us). 
 
The checklist is an initial framework to inform discussion and decision at a relatively high level, to set 
criteria, and ensure that lower tier decisions ± and the reasons for them ± are incorporated into 
minutes and notes of the meetings at which they are taken, thereby enabling a dynamic process of 
comparison and consolidation as cases accumulate.  In our approach, what is equitable or inequitable 
is less a matter for a priori definition than for discovery and subsequent categorization by those 
appointed by legitimate means to make such decisions.  We hope that the checklist will help the 
process of discovering whether a consensus does exist and, where it does not, what the nature of the 
conflict may be and how it might most appropriately be dealt with.  Although the exercise is not 
intended to generate a consensus, establishing that there is no consensus on some of these 
questions is as important as seeking one [45].  While it may be possible to develop a consensus over 
time in a jurisdiction, or at least a consistency in the way equity matters are considered, it seems 
unlikely that such a consensus would ever be achieved across jurisdictions, where prevailing 
standards, cultures and political values could vary greatly. 
 
The object instead is to enable all potentially relevant factors to be clarified and considered, along 
with any evidence pertaining to them, including any evidence generated in the actual process of 
consultation and deliberation.  The process is intended to affect both the procedures of the HTA as 
ZHOODVWKHµILQDODSSUDLVDOGHWHUPLQDWLRQ¶4  It may also be used by agencies to determine the scope of 
equitable issues to be considered by advisory committees, with the consequence that some of the 
matters identified in the list would not in practice be open for discussion. 
 
We propose that the equity checklist should: (a) be used as part of the process through which 
advisory bodies are given their terms of reference, (b) form a part of the scoping agenda prior to the 
selection of a candidate intervention and its comparators for HTA, (c) accompany the usual efficiency-
related statistical and analytical, research and background briefing for decision makers, including 
systematic and other reviews, incorporating any anticipated equity issues in the scoping stage; and 
(d) where appropriate (e.g. when equity issues of sufficient weight are identified to warrant detailed 
consideration) help to structure the discussion and composition of multi-disciplinary, multi-professional 
DQGµOD\¶DGYLVRU\JURXSVGXULQJ the assessment process. 
 
We anticipate that the checklist will be developed in a variety of ways.  One is through academic 
research and discussion, which will in turn inform the methodological guidance of HTA agencies.  
Others, which we have previously characterised as casuistry, are through the gradual building up of 
case studies of actual decisions, their reasoning, and their eventual analysis, synthesis and 
consolidation into statements of good practice at various levels of the decision making process.  This 
will normally require digging deeper than the mere on-line consultation of the recommendations and 
decisions of advisory committees.  In this fashion, we expect to see an accumulation of case-based 
precedents that will help decision-makers achieve consistency across interventions, constantly remind 
them of factors that might otherwise be overlooked, together with suggestions of how they could be 
handled. 
 
                                                 
3
 It is intended to complement rather than supplant other checklists such as those being developed by the Campbell and 
Cochrane Equity Methods Group (Ueffing et al. [42] and Tugwell et al. [43]). It could also be used as a complement to audits of 
equity such as that operated in England by the Department of Health [44]). 
4
 This is the term used by NICE to describe the recommendation or final product of its evidentiary review process: the guidance 
of its Technology Appraisal Advisory Committee. 
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Elements of the checklist 
 
Equity versus equality 
 
Decision makers may need reminding that equity and inequity are not the same as equality or 
inequality.  When, however, inequalities are linked with postulated causes as when, for example, a 
concentration curve links health or ill-health to income, an inequality might be judged as also 
inequitable.  Some inequalities are actually equitable as when, for example, someone with an urgent 
need to treatment receives it before another who is a less urgent case.  In all cases, however, it is 
ZRUWKDVNLQJµHTXDOLW\RULQHTXDOLW\RIZKDW"¶  Common candidates include: need; deservingness or 
responsibility; capacity to benefit or be harmed; degree of incapacity or current health state; history of 
past health or ill-health; prognosis with and without the technology; health outcome - quality of life; 
and dependents (e.g. care-giving responsibilities).  The ethical element derives from the postulated 
cause of the health inequality. Empirical causes judged to be ethically relevant commonly include 
income and wealth; social class; social deprivation; and life-style and behaviour.  While the solution to 
inequity is likely to require addressing the underlying causes, an assessment of their mutability and 
the balance of cost and benefit in changing them, the range of remedies in HTA is typically narrower, 
lying within health care and typically within a rather small subset of health care technologies. 
 
The language of equality and inequality is explicitly quantitative and it is always worth seeking 
empirical and quantitative information about how equal or unequal the relevant factors, outcomes or 
causes are and how equal or unequal it is felt they ought to be.  Major unjust inequalities may rightly 
be perceived as more important to remedy than minor ones, though the relative costs or redress 
ought normally also to be taken into account.  In all cases a judgement should be made as to whether 
the evidence on equity warrants any significant departure from the implications of the efficiency 
analysis, such as recommending the use of an intervention when its incremental cost-effectiveness 
ratio is above that normally deemed to be the maximum allowable, or not recommending one that is 
below that threshold, on grounds of its inequitable consequences. 
 
Domains of equity 
 
The matters for discussion under this category of the checklist relate to the appropriate focus on 
equity, for example, whether it should relate to health care inputs, processes or outcomes; whether it 
is the direct or indirect (perhaps unintended) consequences of the use and diffusion of the health 
technology that matter; whether there should be a disease focus, with patients being classified by, 
say, diagnostic group, or in some other way (say, by socio-economic status (SES)).  If the 
identification of subgroups within a larger class of individuals could generate inequities, these should 
be explored.  It is at this stage that some groups who might be affected by a technology can be 
(innocently but mistakenly) overlooked, as might be the case in interventions for parents that have 
significant side-effects on children.  Such an omission would, of course, also bias an efficiency 
analysis as well as raising potentially significant equity issues [46].  For example, if we consider a 
screening technology that distinguishes between cancer patients who would benefit from a particular 
treatment from those who would not, then one domain of equity pertains to the consideration the 
implications for both sub-groups: not only the sub-group that benefits but also those who are 
disappointed. 
 
Legal obligations 
 
Most jurisdictions will specify statutory requirements to consider justice and equity and there may be 
further administrative obligations placed on agencies by higher tier organizations or their own 
governing bodies.  Anti-discrimination legislation may be quite specific in requiring specific factors to 
be taken into account and may go so far as to specify how and the discretion that is permitted the 
decision makers.  Legal obligations may be absolute, in the sense that any inequality of the sort in 
question is illegal, or relative in the sense that discretion may be exercised regarding the extent to 
which a given inequality violates a principle of equity.  Common dimensions include discrimination by 
age, religion, gender, disability, ethnicity, race, socio-economic status, nationality, language and 
sexual orientation.  Other dimensions may have regulations we cover under other headings.5 
                                                 
5
 NICE has gone further than most agencies in identifying groups of people for whom special treatment may in some 
circumstances be appropriate. They are: race (ethnicity) only when clinical effectiveness cannot be identified in any other way; 
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General principles 
 
Despite the difficulty in obtaining universal assent to specific ethical principles, it is always worth 
establishing whether some (probably simple) principles would in fact be agreed for all cases or in the 
context of the case under consideration.  Some may be inherently broadly applicable and become 
embodied as standard in the consideration of equity.  Principles that might be worth discussing could 
include: 
 
D7KHGRPDLQRIHTXLW\VKDOOEHµFXUUHQWDQGSURVSHFWLYHKHDOWK¶QRWSDVWKHDOWK 
(b) Equity requires either the attainable equality of something or else its fair inequality. 
(c) Fair inequalities in treatment exist when the inequality arises from a fair claim for being 
treated differently, such as an accepted claim of higher need. 
 
It may also be possible to agree specific axioms relating to equity, such as the following cockshies: 
 
:HDN HTXLW\ D[LRP  µLI SHUVRQ A has a worse state of health than person B, then in 
determining the equitable allocation of an intervention having a given impact on a population 
including A and B the equitable solution ought to increase A¶VKHDOWKPRUHWKDQB¶VRUUHGXFH
LWOHVV¶ 
 
or 
 
Weak equity axiRP  µLI SHUVRQ A has a worse state of health than person B, then in 
determining the equitable allocation of a budget for interventions on a population including A 
and B the solution ought to include only interventions that on average increase A¶V KHDOWK
more than B¶VRUUHGXFHLWOHVV¶ 
 
Embedded inequity 
 
By embedded inequity we mean inequities arising from inherent characteristics of the analysis or 
intervention.  This might arise from the use of specific concepts or tools.  For example, it is generally 
recognised that the use of EQ-5D might discriminate unfairly against clients with cognitive impairment 
or with sensory deficits for whom it is not well-designed.  Unfairness might also arise in the detail of 
the measurement process ±  EQ-5D may omit significant dimensions and thereby unfairly discriminate 
against patients for whom the omitted factors are key outcomes, such as relief of fatigue for people 
living with rheumatoid arthritis or anaemia.  Time costs may not properly reflect opportunity costs for 
different social/employment groups, as when salary earners do not lose income when attending a 
clinic compared with the self-employed.  Practical measurement and experimental methods may 
contain inequitable framing biases, or measures of inequality may over or underweight the extremes 
of a distribution of benefits or harms [48] or exclude relevant dimensions [49]. 
 
The systematic exclusion of vulnerable groups from clinical trials/research can lead to an absence of 
evidence on effectiveness in those groups, which in turn can result in inequitable denial of access.  A 
now classic case of this bias is the exclusion of women from cardiovascular clinical trials despite the 
prevalence rate of cardiac disease amongst them (see Kim et al. 2009 [50]). 
 
Embedded inequity might also arise from the inherent character of an intervention, such as denial of 
choice that can arise in some interventions such as water fluoridation, population-screening programs 
or (healthy) fixed school lunch menus, where the affront to freedom may bear more heavily on some 
than on others, such as those with religious dietary restrictions.  The commonly made assumption that 
a quality-adjusted life year is of equal social value to whomever it accrues is an embedded 
assumption that may need modification if it is thought that the value (weight) placed on a QALY gain 
for one who is currently very sick ought to be higher than for one less sick [23]. 
 
Inequity may arise when the valuation basis of health outcomes is variable as when, for example, 
those who have actually experienced a condition (and its treatment) value its avoidance less than 
                                                                                                                                                        
disability, especially where there are obstacles to their benefitting from a technology; age, sex or sexual orientation, if they are 
an indicator of benefit or risk or clinical effectiveness cannot be identified in any other way; stigma, to the extent that it affects 
behaviour and the probability of benefit; behaviour-dependent conditions only if continuing behaviour affects the probability of 
benefit; socio-economic status only if effectiveness is linked to status or there is a legal requirement to favour this group [47].  
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those who anticipate but have not experienced it [51].  More generally, if the prevalence of unstable 
valuations of outcomes is related to other characteristics, such as education or social class, then a 
suitable precaution might be to discover the views of those most directly affected by the intervention 
in question.  There is a great deal of evidence of the considerable variability of preferences and 
valuations, and their susceptibility to framing and other effects, in the literature of cognitive 
psychology and experimental economics (e.g. Kahnemann and Tversky 2000 [52]). 
 
Institutional bias 
 
Institutional biases are those that are also embedded but in organizations rather than analytical 
methods or interventions.  The equity issue here is whether the jurisdictional scope of agency or of its 
parent organization causes any costs or benefits that might be significant for equity to be omitted or 
distorted.  For example, if major outcomes include effects such as reductions in teenage pregnancies 
or a reduction in the frequency of j-ZDONLQJ WKHVHPD\QRWEHDSDUWRID0LQLVWU\RI+HDOWK¶VUHmit, 
belonging instead to a Ministry of Social Work or the Ministry of Transport.  Conversely, the 
MXULVGLFWLRQDO VFRSH RI µSDUWQHU¶ DJHQFLHV RU PLQLVWULHV PLJKW FDXVH VLJQLILFDQW FRVWV RU EHQHILWV IRU
health equity to be omitted or distorted (such as impacts on life expectation). 
 
Other skews may exist in the distribution of the costs and benefits of interventions across 
µVWDNHKROGHUV¶ WKDW FUHDWH LQHTXLW\ DV ZKHQ ZRUNSODFH LQWHUYHQWLRQV KDYH FRVWV WKDW IDOO PDLQO\ RQ
owners and benefits that fall mainly on workers [53].  Institutional biases may cut across a myriad of 
domains, including the highest institutional levels such as health ministries, within agencies 
conducting technology appraisals, in provider institutions, in workplaces and other locations of care or 
intervention. 
 
Implicit stereotyping 
 
Implicit stereotyping occurs when assumptions are made about a condition and the desirability of 
WUHDWLQJ LW VR DV WR DVFULEH WKRVH OLYLQJ ZLWK WKDW FRQGLWLRQ DV µDEQRUPDO¶ RU µXQGHVLUDEOH¶ [54].  For 
example, individuals who are deaf like to consider themselves as a group distinguished not only by 
deafness but also by D ODQJXDJH 6LJQ DQG UHVLVW WKH GHVFULSWRU µGLVDEOHG¶ RQ WKH JURXQGV WKDW
deafness is, in effect, a socially-FRQVWUXFWHG µGLVDELOLW\¶DQG WKHUHIRUHQHHGQRWEH µWUHDWHG¶  Implicit 
VWHUHRW\SLQJ LV HVSHFLDOO\ OLNHO\ ZKHQ WKH FXOWXUH RI WKH µSDWLHQW¶ GLIIHrs from that of the analyst.  A 
GUDPDWLF H[DPSOH RI WKH ZD\ LQ ZKLFK µGLVHDVH¶ FDQ EH VRFLDOO\ FRQVWUXFWHG LV SLQWD G\VFKURPLF
spirochaetosis).  This skin disease produces distinctive rose-coloured spots on the skin, which some 
Indians in South America once believed to be a sign of being healthy, and which was so prevalent 
among some tribes that the few single men not suffering from it were regarded as pathological to the 
point of being excluded from marriage [55]6.  To treat it therefore according to concepts of disease 
which are external to that culture is likely to imply that the value of treatment thus estimated would 
conflict with a value based on local Indian concepts and values.  The danger for HTA in implicit 
stereotyping is that the externally perceived health gain relative to that perceived by the patient can 
be substantially different, and subsequent implementation becomes patronising or even stigmatizing. 
 
Implicit stereotyping may be particularly expected for congenital and other chronic conditions.  A 
check is actually to ask the target populations concerned through consultation and deliberation 
whether the measure or conceptualization of the health benefit or state is biased ± or whether there 
may be some members of the target group for whom this might be the case. 
 
Contexts, behaviours and circumstances 
 
This category includes aspects of the context of technology use that could, at least in principle, 
disadvantage some people relative to others (e.g. traveling from a remote home to a clinic or hospital) 
and thereby render an intervention cost-effective for one group but not for another (e.g. [31]).  Any of 
the following circumstances could affect the balance of negative and positive consequences: 
demographics (age, sex, ethnicity, socio-economic status (SES)), location of delivery of care (e.g. 
home or institution), language, religious beliefs, sexual orientation, or multiple deprivation. 
 
                                                 
6
 This interpretation is not uncontroversial, see Frankel (1986) pp 2-3 [56], but the social construction remains. 
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Some effects occur in unanticipated ways.  For example, it was found in Rich et al. (1976) that the 
reliability of self-administered dipslide measures of bacteriuria taken at home by girls without 
symptoms varied significantly with the age and socio-economic status of the children performing the 
tests compared with costlier supervised sampling of the same girls [57].  In such cases, the cost-
effectiveness of an intervention that is in all other respects the same will be higher for the younger 
and/or lower SES children. 
 
There is considerable evidence that differential behavioural responses to public health measures 
according to SES may actually contribute in an unintended way to inequity, especially when utilization 
of an intervention LV ORZHUDPRQJPRUHGLVDGYDQWDJHGDQG µKDUG-to-UHDFK¶SRSXODWLRQVRUE\HWKQLF
minorities [8].  It can be all-SHUYDGLQJIRUZKLFKWKHWHUPµVWDLUFDVHHIIHFW¶ZDVFRLQHGE\7XJZHOOHWDO
[58].  Unintended inequality-ZLGHQLQJ LQWHUYHQWLRQV KDYH EHHQ WHUPHG µLQWHUYHQWLRQ JHQHUDWHG
LQHTXDOLWLHV¶ [59].  These are widespread phenomena and have been found to exist, for example, in 
many preventive interventions [60, 61].  There is also, needless to say, abundant evidence that many 
interventions also generate greater health equality [58]. 
 
More generally, equity concerns may arise whenever a particular technology is cost-effective for some 
subgroups of clients but not others [38] whether for behavioural or other reasons, depending again on 
the social and economic characteristics of the subgroups. 
 
Processes in HTA 
 
Anticipated equity effects that require adaptation of the usual review processes of the agency need to 
be considered and addressed as early as possible in the HTA, including the scoping stage.  Thus, all 
questions concerning rights of different groups to be consulted, represented or to participate in 
decision making processes should be considered not only in terms of the expertise, knowledge and 
understanding that they may bring to the process but also with regard to fairness.  For example, if a 
manufacturer or a patient group may be affected for good or ill by the HTA process, it is likely that 
fairness would at least require their right to participate to be considered. 
 
If the outcome measure of choice may not be valid for some patients, perhaps because some aspect 
of health benefit is not included among the dimensions of the measure, then the procedure should 
ensure that decision makers have access to patients and informal carers with experience of the 
condition and its treatment to enable the construct validity of the measure to be assessed and, if 
necessary, to enable appropriate adjustments.  This approach was employed recently by the Medical 
Advisory Secretariat in Ontario during their scoping stage of an HTA, where they sought patient input 
on the research questions to ensure that they captured relevant patient outcomes in their evidentiary 
review [31]. 
 
Hidden opportunity costs 
 
These are costs imposed on those affected by the intervention and anonymous people who are 
affected through consequential changes in the distribution of resources.  The identity of the individuals 
who lose may not be known.  The weight to be attached to any such opportunity cost might vary 
according to what is known about who are most likely to lose compared with those directly affected by 
the intervention.  One group of stakeholders that is almost invariably omitted from the deliberative 
pURFHVVHV LV WKH µRUGLQDU\¶RUpotential consumer of health care ± that is, members of the public (as 
distinct from representatives of specific patient advocacy organisations).  By definition, these are 
anonymous individuals whose stakeholder status arises from the fact that their taxes or premiums 
fund health care budgets, and if some of these budgets are spent on one intervention, those parts are 
not available for others including interventions for these ordinary and potential consumers.  While this 
opportunity cost provides the underpinning argument for using a test incremental cost-effectiveness 
ratio (ICER) and is a conventional part of the efficiency element of an HTA, the possibility arises that 
there may also be equity considerations.  For example, when the beneficiaries of a proposed new 
intervention are relatively privileged or underprivileged members of the community (or few in number) 
FRPSDUHGZLWKWKHµRUGLQDU\¶FRQVXPHU 6LPLODUO\WKHµRUGLQDULQHVV¶RIWKRVHZKREHDUWKHRSSRUWXQLW\
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costs of newly introduced interventions ought to be tested.  Empirical ways in which this might be 
done are, however, very much at the research stage.7 
 
Processes in the delivery of care 
 
Processes in the delivery of care might have inequitable consequences even in the absence of 
institutional bias of the type already outlined.  For example, the way in which care is delivered may be 
demeaning or unduly revealing, as when a patient enters an HIV or STD clinic having a sign publicly 
indicating its purpose.  There may be processes at local delivery sites that deny opportunities for 
patients to reveal equity-related factors.  For example, it is commonly charged that middle class 
clients of health care systems are more adept at managing their way through administrative 
processes and hence of receiving effective health care [62].  A flagrant breach of equity arises when 
health care providers select out patients deemed to be less financially advantageous to the 
organisation by virtue, for example, of the chronicity of the disease or their insurance status. 
 
Special claims 
 
There is a range of frequently heard specific equity claims that ought to be anticipated and appraised 
both in the scoping of an HTA and at subsequent stages.  A position should be taken as to what 
categories of claims will be entertained.  Commonly met claims include: claims of need, such as low 
initial health status; claims of responsibility, which may be positive if, say, the likely beneficiaries are 
deserving by virtue of their roles as, for example, parents, or negative if, say, the likely beneficiaries 
DUH GHHPHG µXQGHVHUYLQJ¶ E\ YLUWXH RI EHKDYLRXU VXFK DV SXUVXLQJ OLIH VW\OHV KD]DUGRXV WR KHDOWK
claims of history, such as past endurance of ill-health or previous receipt of the intervention; claims of 
desperation, as when the intervention LQ TXHVWLRQ UHSUHVHQWV D µODVW FKDQFH¶ IRU D FXUH FODLPV RI
unfair innings, such as a short already-lived life-span [63]; claims related to non-health consequences 
(other effects on welfare) or on multiple deprivations; claims of willingness to pay such as a 
willingness to µWRS-XS¶WRFRPSHQVDWHWKHSURYLGHUIRUSURYLGLQJFDUHWKDWLVOHVVFRVW-effective than the 
WKLUGSDUW\SD\HU¶VWKUHVKROGUHTXLUHV 
 
Special claims and possible inequity may arise in connection with individuals who are not themselves 
patients.  While it is commonplace in efficiency studies to recognize the importance of taking account 
of the impact of technologies on informal carers, carers too may have circumstances or characteristics 
that warrant special consideration on grounds of equity, especially if they have carried very heavy 
physical and emotional burdens while caring [64].  It is important not to be misled by spurious special 
claims from interest groups but it is equally important not to allow the strongest of special claims to go 
unappraised or to overlook the interests of those who are not organized or equipped to ensure that 
their claims are. 
 
Cumulative effects 
 
The consideration of cumulative past disadvantages or advantages that might be relevant in 
assessing benefit or cost or their distribution across affected parties would enable a broad view to be 
WDNHQ DQG KHOS WR HQVXUH WKDW WKH µZKROH¶ ZDV QRW WDNHQ XQFULWLFDOO\ WR EH PHUHO\ WKH VXP RI WKH
LQGLYLGXDO µSDUWV¶  The accumulation might be across many equity categories, or over time, or both.  
The possibility ought to be considered that such accumulation strengthens any case for redress. 
 
7KHVHFDWHJRULHVDUHVXPPDUL]HGLQWKHIROORZLQJµFKHFNOLVW¶LQZKLFKZHKDYHLQFOXGHGµSURPSWV¶WR
stimulate discussion and the assessment of the relevance of the category in question. 
 
                                                 
7
 The topic is being investigated by a group led by Karl Claxton and Mark Sculpher at York (UK) researching value-based 
pharmaceutical pricing. 
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Conclusions 
 
We have provided a framework for developing a checklist of equity considerations to complement the 
standard efficiency calculus of HTA.  It is intended be used as part of the process through which 
advisory bodies are given their terms of reference; the scoping of the agenda prior to the selection of 
candidate interventions and their comparators for HTA; the accompanying background briefing for 
decision makers, including systematic and other reviews; and as a tool to help to structure the 
GLVFXVVLRQDQGFRPSRVLWLRQRISURIHVVLRQDODQGµOD\¶DGYLVRU\JURXSVGXULQJWKHDVVHVVPHQWSURFHVV  
Its effective development and implementation depends upon the creation of an on-going research 
program that identifies omissions and on HTA processes that provide, through appropriately detailed 
minuting and note-taking, accounts of decisions taken by decision making agencies that can be 
interpreted as precedents and analyzed retrospectively to promote consistency and to understand the 
reasons why apparently similar cases have been adjudicated differently on different occasions.  
Periodic reviews and updating guidance for decision makers are also recommended.  In these ways, it 
may be hoped that equity will be more systematically and fully considered and implemented in both 
the procedures and decisions of HTA. 
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Table 1 A Checklist of equity considerations for health technology assessment 
Domain Elaboration Questions 
1 Equity and equality There can be fair inequalities and unfair equalities.  Equity ought not 
to be equated with equality (of something) but, if it is, the ethical 
µZHLJKW¶WREHDWWDFKHGWRWKHµVRPHWKLQJ¶QHHGVFRQVLGHUDWLRQ  
µ(TXDOLW\¶DQGµLQHTXDOLW\¶LPSO\DGHJUHHRITXDQWLfication (minimally 
DQRUGHURIVWDWHVRIµPRUH¶RUµOHVV¶  Check on empirical research 
for quantified measures of inequity.  In the absence of good quality 
UHVHDUFKLGHQWLI\RWKHUVRXUFHVVXFKDVµH[SHUWRSLQLRQ¶EXWEHDOHUW
WRWKHSRVVLELOLW\RIµH[SHUWSUHMXGLFH¶ 
Equality (or inequality) of what?  Common candidates include: need, deservingness or 
responsibility, capacity to benefit (or be harmed), degree of incapacity or current health 
state, history of past health or ill-health, prognosis with and without the technology; health 
outcome - quality of life; and dependents (care-giving responsibilities).  Need to seek 
empirical and quantitative information about how equal or unequal the relevant factors 
are. 
2 Adequacy of the 
domains of equity 
The focus of the analysis of equity.  This could be on health care 
inputs, processes, direct outcomes, indirect outcomes, disease 
patterns, patient types, subgroups.  The desired focus is likely to be 
context-dependent and may depend on the rulings of a higher tier 
authority.  
Should the domain of equity relate to health care inputs, processes or outcomes?  Might 
there be unintended consequences that raise equity issues?  Should the domain of 
analysis be disease focused; or should some other basis for differentiating individuals and 
subgroups be used?  What are the equity-related consequences of this categorization? 
3 Legal obligations Common offences include discrimination by age, gender, disability, 
ethnicity, race, nationality, language, sexual orientation, in the 
workplace, in education; there are also institutionalized 
discrimination, implicit and indirect discrimination. 
Have the relevant local legal obligations concerning age, gender, disability, ethnicity, 
race, nationality, language, sexual orientation, etc. been considered?  Are there any 
legislative requirements concerning institutionalized, implicit or indirect discrimination, in 
the respective jurisdiction? 
4 General principles 0LQLPDOUHTXLUHPHQWVIRUµHTXLW\¶D[LRPDWLFVWDWHPHQWVDSSOLFDELOLW\
of such principles in current context. 
Have a set of guiding principles or axioms been established concerning what constitutes 
equality (or fair inequalities) in the current context?  Is it possible to infer specific equitable 
guidance in the current context from the general guidance?  Are their precedents that 
could guide in the present context? 
5 Embedded inequity 3RVVLEOHXQIDLUQHVVµEXLOWLQ¶WRFRQFHSWVHJRPLWWHGGLPHQVLRQVRI
outcome or cost), framing effects in experimental approaches, 
possible unfairness inherent in the intervention (e.g. threat to 
autonomy). 
Are there inequities in the measurement or methodological processes informing the HTA?  
For example, does the outcome measure omit significant dimensions and thereby 
differentially exclude key outcomes for some groups?  Are the standard weights attached 
to gains and losses affecting different people (usually but not necessarily, unity) deemed 
suitable in the current context?  Do the measures of inequity weight distance from the 
average in an acceptable way?  Are there any aspects of the intervention, in addition to 
the direct effects, that may raise equity concerns? 
6 Institutional bias Inequity resulting from jurisdictional scope in clinical practices, 
provider institutions, workplaces, or in the distribution of 
consequences. 
Do any of the following cause particular costs or benefits to be omitted or distorted: the 
DJHQF\¶VSDUHQWRUJDQL]DWLRQWKHFXOWXUHRIWKH+7$DJHQF\LWVHOISURYLGHULQVWLWXWLRQV
workplaces? 
7 Implicit stereotyping Definitions and concepts that exclude or prejudice individuals.  
Aspects of the effects of the intervention that have differential impact 
on individuals, or which make in untested assumptions about what 
GRHVDQGGRHVQRWµPDWWHU¶RUDUHVWLJPDWL]LQJ 
Is the measure or conceptualization of the health benefit or cost or state biased?  Have 
DVVXPSWLRQVDERXWZKDWµPDWWHUV¶EHHQWHVWHGE\FRQVXOWLQJWKRVHDIIHFWHG" Is the 
current context one in which there are likely to be marked differences in culture between 
analysts and client groups that could give rise to implicit stereotyping?  Are there people 
who might be affected but whose interests have not been taken into account? 
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8 Contexts and 
circumstances 
Aspects of the context that could disadvantage some relative to 
others (e.g. geography, culture), tests for whether any of the 
following could affect the balance of advantage:  Usual 
demographics (age, sex, ethnicity, SES), location of delivery (e.g. 
home or institution), language, education of clients, religious beliefs, 
sexual orientation, stigma, multiple deprivation.  Aspects of the 
context that render the proposed methods of HTA inappropriate 
(e.g. methods used in a high-income country being applied in a low-
LQFRPHFRXQWU\µZHVWHUQ¶YDOXHVEHLQJDSSOLHGLQDQaboriginal or 
µILUVWQDWLRQV¶FRQWH[W 
Do any of the following circumstances affect the balance of negative and positive 
consequences: geography, demographics (age, sex, ethnicity, socio-economic status), 
location of delivery of care (e.g. home or institution), education, language, religion, sexual 
orientation, or multiple deprivation?  Are methods developed in one culture being 
appropriately applied in another? 
9 Processes in HTA Process that deny suitable representation to people with a legitimate 
interest, processes that deny consideration of the interests of 
absentee stakeholders. 
Has the scoping of the HTA caused a bias in the processes through which information 
germane to equity is gathered or considered?  Is the current guidance devoid of any 
implicitly biasing elements, such as the exclusion of relevant consultation groups, in the 
current context?  If not, can the matter be addressed and rectified?  Are the appropriate 
health outcomes measures and stakeholders included in the HTA process (including 
patients and members of the public)?  
10 Hidden opportunity 
costs 
These refer to costs inflicted on those affected indirectly by the 
intervention and those anonymous people who are affected through 
consequential changes in the distribution of resources if the 
recommendations of the HTA were implemented.  The identity of the 
individuals who lose may not be known.  It may also be that the 
weight to be attached to any such opportunity cost might vary 
according to what is known about those most likely to be losers 
relative to those directly affected by the intervention. 
Has due regard been had to the interests of the anonymous clients of the health care 
system from whom resources will be removed as a consequence of the implementation of 
the recommendation of the HTA?  Do those most likely to be affected in this way have 
distinctive characteristics suggesting that differential weights ought to be attached to the 
impacts on them?  Are there any empirical estimates of any such relevant effects? 
11 Processes in 
delivery of care 
Processes in the delivery of care that are prejudicial to, demeaning 
of or embarrassing for some who are affected.  Some processes 
favour those adept at managing their way through complex or 
unfamiliar processes.  Thus, other inequities for those lacking such 
social skills or that impose differential costs/burdens on some clients 
and stakeholders relative to others might not be known or even 
revealed. 
Are there processes in the delivery of care, apart from those that are embedded in 
institutions that discriminate unfairly?  Are any of the likely delivery processes prejudicial 
to, demeaning of or embarrassing for some clients relative to others?  ,VWKHUHDµPLGGOH
FODVV¶ELDVWKDWIDYRXUVWKRVHZLWKVNLOOVDWGHDOLQJZLWKUHFHSWLRQLVWVEXUHDXFrats, 
professionals and other unfamiliar groups of people? 
 
12 Special claims Claims such as claims of need (e.g. low initial health status?), 
claims of responsibility (e.g. life styles hazardous to health), claims 
of history (e.g. past endurance of ill-health, past receipt of the 
LQWHUYHQWLRQFODLPVRIGHVSHUDWLRQHJµODVWFKDQFH¶FODLPVRI
unfair innings (lived life-span), claims of non-health consequences 
(other welfare effects), claims of willingness to pay (e.g. top-ups). 
What, if any, special claims ought to be considered?  Are there claims or interests not 
being heard but deserving of voice?  Are their claims that are not ethically significant?  
Can the claims that might carry weight bear empirical testing for their veracity and size?  
Are there precedents for dealing with claims of the sort in the current context?  How do 
special claims compare to the putative claims of those not represented in the HTA 
process? 
13 Cumulative effects Consideration of cumulative past disadvantages or advantages that 
might be relevant in assessing benefit or cost or their distribution 
across affected parties. 
+DVDKROLVWLFSHUVSHFWLYHEHHQWDNHQRUPHUHO\WKHVXPRIWKHLQGLYLGXDOµSDUWV¶" Have 
historical disadvantages been considered?  Are there any other respects in which the 
cumulative experience or the combination of experiences of those affected may be of 
equitable concern? 
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